Pharmaceutical TechnologyOriginal article
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
PartnershiplacutamabPositive
AI Analysis
Summary
Innate Pharma licenses lacutamab to Sobi for up to $580 million with plans to initiate a Phase III confirmatory trial for rare cutaneous T-cell lymphoma, seeking accelerated approval.
Clinical Trial Data
Phase
Phase III
Outcome Details
Licensing agreement up to $580 million
Importance:7/10
Sentiment:
0.70
licensing dealrare diseaseaccelerated approval pathwayPhase III
Read the original article
Published by Pharmaceutical Technology on August 10, 2026 11:14 AM